X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

    INOVIO to Develop dMAb COVID Treatments under DARPA Grant

    Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

    Thermo Fisher Expands Clinical Supply Services in Europe

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    Abzena Invests $60M Into cGMP Manufacturing Capacity

    COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

    The UK begins the biggest ever immunization program

    The UK begins the biggest ever immunization program

    Russia roll out the homegrown Sputnik V vaccine for its population

    Russia roll out the homegrown Sputnik V vaccine for its population

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

    INOVIO to Develop dMAb COVID Treatments under DARPA Grant

    Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

    Thermo Fisher Expands Clinical Supply Services in Europe

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    Abzena Invests $60M Into cGMP Manufacturing Capacity

    COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

    The UK begins the biggest ever immunization program

    The UK begins the biggest ever immunization program

    Russia roll out the homegrown Sputnik V vaccine for its population

    Russia roll out the homegrown Sputnik V vaccine for its population

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

Content Team by Content Team
17th December 2020
in Drug Development, News
Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

DNA damage response (DDR)-focused Artios Pharma has signed a global strategic collaboration with the Merck Group to discover and develop multiple precision cancer drugs.

According to the terms of the agreement, the partners will leverage Artios’s DNA repair nuclease discovery platform to identify synthetic lethal targets for novel drug candidates. Merck will have the exclusive rights to develop and commercialise therapies discovered under the collaboration.

In return, Artios will gain access to Merck’s DDR expertise and resources and receive $30m in upfront and near-term payments. Artios may also be eligible to receive up to $860m per target commercialised, as well as double digit royalty payments.

Artios chief business officer Tania Dimitrova explains Artios will spend the $30m on supporting its existing products, which are excluded from this collaboration with Merck, into clinical trials. Dimitrova notes Artios is hoping to start clinical trials of its two lead products – ataxia telangiectasia and Rad3-related protein (ATR) inhibitor and Pol Theta – into clinical trials by the end of 2021.

CEO Niall Martin adds that the funding will allow Artios to continue to build out its platform and bring forward new targets in the DDR space.

Promise of DDR in cancer

Merck senior vice-president and head of translational innovation platform oncology Andree Blaukat explains: “Cells must identify and repair DNA damage to survive. But cancer cells often develop defects in DDR pathways, leading to the accumulation of mutations in oncogenes and tumour suppressors that enable them to grow in an uncontrolled way and spread throughout the body.”

“However, also cancer cells can only tolerate a certain level of DNA damage and therefore heavily rely on those DDR pathways that are still intact. Selectively inhibiting these DDR pathways can be potentially an effective way to eliminate tumour,” adds Blaukat. This process of selectively killing cancer cells is known as synthetic lethality.

Founded in 2016, Artios focuses on finding “new targets and opportunities around DDR to be able to create a toolkit of DNA repair inhibitors that oncologists can have in their armoury to tackle cancer,” explains Martin.

The company builds on Martin’s experience in developing the world’s first PARP inhibitor, olaparib, while working for KuDOS Pharmaceuticals, which was later acquired by AstraZeneca. However, there is a need to look beyond PARP inhibitors as they do not work against all DNA repair changes and genetic mutations. There are also issues with cancer cells developing resistance to PARP inhibitors. “We want to understand what is causing that resistance and be able to give an alternative to PARP inhibitors in the DNA repair space,” notes Martin.

One of the alternatives Artios is exploring is DNA nucleases, which certain cancer cells rely on to survive after DNA damage, according to Blaukat. The discovery of repair nuclease inhibitors is the focus of the Artios’s latest collaboration with Merck.
Combining DDR expertise

Blaukat explains the two companies have great “synergy potential”. He adds: “We look forward to combining our extensive R&D expertise in the field of DDR with their nuclease-targeting discovery platform”.

“This collaboration further strengthens our leadership and expertise in the field of DDR inhibitors and complements our multiple innovative assets currently being evaluated in research and in several Phase I and Phase II clinical studies,” continues Blaukat. Merck’s DDR portfolio focuses on three targets – ataxia-telangiectasia mutated kinase, ATR, and DNA-dependent protein kinase.

Dimitrova explains that Merck is “truly the perfect partner” for Artios. The company stood out to Artios because of its “passion for the DDR” and the clear strategic importance Merck placed on this this treatment paradigm.

Partnerships are central to Artios’s business model because it wants to “be the best in DDR and really change outcomes for patients”. “To do that, it is important to collaborate with the best in the world”, concludes Dimitrova.

Previous Post

INOVIO to Develop dMAb COVID Treatments under DARPA Grant

Next Post

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Related Posts

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

17th December 2020
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Drug Development

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

17th December 2020
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
Drug Development

INOVIO to Develop dMAb COVID Treatments under DARPA Grant

17th December 2020
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing
Clinical Trials

Thermo Fisher Expands Clinical Supply Services in Europe

17th December 2020
Takeda
News

AstraZeneca and J&J COVID-19 Shots Crucial To Meet US Vaccination Goal

14th December 2020
Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine
News

Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

14th December 2020
Next Post
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Latest News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

17th December 2020
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Drug Development

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

17th December 2020
Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery
Drug Development

Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

17th December 2020
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
Drug Development

INOVIO to Develop dMAb COVID Treatments under DARPA Grant

17th December 2020
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing
Clinical Trials

Thermo Fisher Expands Clinical Supply Services in Europe

17th December 2020
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In